A breakthrough single peptide triple hormone receptor agonist activating GLP-1, GIP, and Glucagon receptors, demonstrating up to 24.2% mean weight reduction in phase 2 trials.
~144 hours (approx. 6 days)
GLP-1 Receptor
C221H342N46O68
Investigated in phase 2/3 trials as a once-weekly subcutaneous injection with step-wise dose titration (1 mg to 12 mg).
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Retatrutide: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C221H342N46O68
Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-Lys-Ala-Gln-{Aib}-Glu-Phe-Ile-Glu-Trp-Leu-Leu-Gln-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (conjugated with diacid fatty chain)
Retatrutide (LY3437943) is an investigational unimolecular agonist engineered with balanced potency across all three key metabolic incretin and endocrine receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). By recruiting glucagon receptor signaling alongside dual incretin action, Retatrutide uniquely stimulates hepatic energy expenditure and lipid catabolism while mitigating hyperglycemic rebound.
Triple agonist engagement: GLP-1 and GIP signaling slow gastric emptying, enhance glucose-dependent insulin secretion, and induce hypothalamic satiety, while glucagon receptor activation stimulates hepatic beta-oxidation, thermogenesis, and basal metabolic rate.
Peer-reviewed publications, clinical trials, and preclinical research investigating Retatrutide.
Landmark phase 2 trial published in the New England Journal of Medicine demonstrating unprecedented weight reduction of up to 24.2% over 48 weeks with the GIP/GLP-1/Glucagon triple agonist retatrutide.
Documented literature dosing intervals and published clinical trial protocols.
Frequency: Once weekly
“Dose escalated monthly across 2 mg, 4 mg, 8 mg up to target 12 mg weekly.”
Frequency: Once weekly
“Dose escalated monthly across 2 mg, 4 mg, 8 mg up to target 12 mg weekly.”
Biological delivery routes and standardized laboratory reconstitution principles.
Investigated in phase 2/3 trials as a once-weekly subcutaneous injection with step-wise dose titration (1 mg to 12 mg).
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolPeer-reviewed Phase 2 trial data in NEJM demonstrates substantial dose-dependent body weight reductions of up to 24.2% with the GIP/GLP-1/Glucagon triple agonist retatrutide.
Read ArticleDual and triple receptor agonists demonstrate potent anti-fibrotic and lipid-clearing actions in phase 2 trials targeting non-alcoholic fatty liver disease.
Read ArticleCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
